Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
16
7
2021
Statut:
ppublish
Résumé
A recent study in mice points to the gut-derived hormone glucagon-like peptide 2 (GLP-2) as an important regulator of gallbladder motility inducing gallbladder relaxation and refilling. In this study, we evaluated the effect of exogenous GLP-2 on postprandial gallbladder motility in healthy men. In a randomized, double-blinded, placebo-controlled, crossover study, we evaluated the effect of 4-hour intravenous infusions of high-dose GLP-2 (10 pmol × kg × min), low-dose GLP-2 (1 pmol × kg × min), and placebo (saline) on postprandial gallbladder motility. A 300-kcal liquid-mixed meal (added 1.5 g of acetaminophen for indirect measurement of gastric emptying) was served 30 minutes after start of intravenous infusions. Gallbladder volume was assessed by ultrasonography. Fifteen healthy men, age 24.3 (22.4-26.1) years (mean [95% confidence interval]) and body mass index 22.5 (21.7-23.4) kg × m, were included. Basal plasma GLP-2 concentration was 14 (11-17) pmol/L. During low-dose and high-dose GLP-2 infusions, steady-state postprandial plasma GLP-2 concentrations amounted to 201 (188-214) and 2,658 (2,443-2,873) pmol/L, respectively, compared with maximum postprandial plasma GLP-2 concentration of 34 (25-44) pmol/L during placebo. Gallbladder emptying (assessed as baseline-subtracted area under the curve for gallbladder volume) was reduced by low-dose GLP-2 (-0.8 [0.7-1.9] L × min, P < 0.0001) and nearly abolished by high-dose GLP-2 (1.3 [-1.7 to 0.01] L × min, P = 0.029) compared to placebo (-2.0 [-2.8 to -1.1] L × min). Compared to placebo, gastric emptying was reduced by high-dose GLP-2 (P = 0.0060 and 0.019), whereas low-dose GLP-2 did not affect gastric emptying (P = 0.13 and 0.85). Exogenous GLP-2 exerts a dose-dependent inhibitory effect on postprandial gallbladder emptying in healthy men.
Identifiants
pubmed: 33512799
doi: 10.14309/ctg.0000000000000257
pii: 01720094-202012000-00007
pmc: PMC7710225
doi:
Substances chimiques
Glucagon-Like Peptide 2
0
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00257Références
Obes Surg. 2012 Jul;22(7):1084-96
pubmed: 22359255
Eur J Endocrinol. 2014 Oct;171(4):407-19
pubmed: 24986531
Diabetes Care. 2013 May;36(5):1396-405
pubmed: 23613599
J Clin Invest. 1991 Feb;87(2):415-23
pubmed: 1991827
Mol Endocrinol. 2011 Jun;25(6):1066-71
pubmed: 21454404
World J Gastroenterol. 2018 Nov 21;24(43):4870-4879
pubmed: 30487697
Regul Pept. 2010 Jan 8;159(1-3):67-71
pubmed: 19900491
Diabetologia. 2007 Oct;50(10):2135-42
pubmed: 17676310
Annu Rev Physiol. 2014;76:561-83
pubmed: 24161075
Bone. 2009 Nov;45(5):833-42
pubmed: 19631303
Curr Gastroenterol Rep. 2004 Apr;6(2):151-62
pubmed: 15191695
J Clin Endocrinol Metab. 2000 Aug;85(8):2884-8
pubmed: 10946898
Oncotarget. 2015 Aug 21;6(24):20661-71
pubmed: 25970782
Acta Radiol. 1990 Nov;31(6):591-6
pubmed: 2278784
Clin Transl Gastroenterol. 2016 Feb 04;7:e142
pubmed: 26844839
Gut. 1996 Nov;39(5):661-7
pubmed: 9026479
Lab Invest. 2015 Feb;95(2):124-31
pubmed: 25502177
Gut. 2005 Sep;54(9):1224-31
pubmed: 16099790
Curr Opin Endocrinol Diabetes Obes. 2015 Feb;22(1):14-20
pubmed: 25485516
J Clin Ultrasound. 1996 Jul-Aug;24(6):277-85
pubmed: 8792267
Neurogastroenterol Motil. 2001 Jun;13(3):179-85
pubmed: 11437980
Gastroenterology. 2012 Dec;143(6):1473-1481.e3
pubmed: 22982184
Clin Chem. 1998 May;44(5):991-1001
pubmed: 9590372
Regul Pept. 2003 Nov 15;116(1-3):21-5
pubmed: 14599711
AJR Am J Roentgenol. 1985 Nov;145(5):1009-11
pubmed: 3901703
Regul Pept. 2010 Aug 9;163(1-3):96-101
pubmed: 20580750
Curr Gastroenterol Rep. 2003 Aug;5(4):302-9
pubmed: 12864960
Peptides. 2000 Jan;21(1):73-80
pubmed: 10704722
World J Gastroenterol. 2010 May 7;16(17):2075-9
pubmed: 20440847
Scand J Gastroenterol. 2009;44(3):314-9
pubmed: 19005872
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2463-2472
pubmed: 30137354
Gastroenterology. 2006 Jan;130(1):44-54
pubmed: 16401467
Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1038-44
pubmed: 20705903
Gut. 2009 Aug;58(8):1091-103
pubmed: 19240062
Int J Obes Relat Metab Disord. 2003 Apr;27(4):450-6
pubmed: 12664078
Front Endocrinol (Lausanne). 2017 Apr 13;8:47
pubmed: 28450850
Mol Metab. 2017 Mar 31;6(6):503-511
pubmed: 28580281
J Gen Physiol. 2002 Mar;119(3):251-73
pubmed: 11865021
Nat Med. 2006 Nov;12(11):1253-5
pubmed: 17072310
Scand J Gastroenterol. 2004 Apr;39(4):353-8
pubmed: 15125467
Gastroenterology. 1980 Jul;79(1):40-6
pubmed: 7380222